Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
Protalix BioTherapeutics (NYSE American: PLX) will release its financial results for the quarter ended September 30, 2025 and provide a business update on November 13, 2025.
Management will host a conference call at 8:00 a.m. Eastern Standard Time with toll-free and international dial-ins and a live webcast. Participants are asked to join 15 minutes early to register and install any required audio software. A replay will be available for two weeks on the company's Investors Events Calendar.
Protalix BioTherapeutics (NYSE American: PLX) presenterà i risultati finanziari del trimestre chiuso il 30 settembre 2025 e fornirà un aggiornamento sull’attività il 13 novembre 2025.
La direzione organizzerà una conferenza telefonica alle 8:00 a.m. ora standard orientale (EST) con numeri senza costo e internazionali e una trasmissione in diretta. Si invita i partecipanti ad accedere 15 minuti prima per registrarsi e installare eventuali software audio richiesti. Una replica sarà disponibile per due settimane sul Calendario degli Eventi per gli Investitori della società.
Protalix BioTherapeutics (NYSE American: PLX) publicará sus resultados financieros del trimestre finalizado el 30 de septiembre de 2025 y proporcionará una actualización comercial el 13 de noviembre de 2025.
La dirección llevará a cabo una llamada de conferencia a las 8:00 a.m. hora estándar del este (EST) con números de acceso gratuitos e internacionales y una transmisión en vivo. Se solicita a los participantes unirse 15 minutos antes para registrarse e instalar cualquier software de audio necesario. Una repetición estará disponible durante dos semanas en el Calendario de Eventos para Inversores de la empresa.
Protalix BioTherapeutics (NYSE American: PLX)는 분기 실적 발표를 2025년 9월 30일로 확정하고 2025년 11월 13일에 사업 업데이트를 제공합니다.
경영진은 오전 8:00 동부 표준시(EST)에 toll-free 및 국제 다이얼인과 라이브 웹캐스트를 통해 컨퍼런스 콜을 주최합니다. 참가자는 등록 및 필요한 오디오 소프트웨어 설치를 위해 15분 일찍 참여해 주시기 바랍니다. 두 주간 회사의 투자자 이벤트 달력에서 리플레이를 이용하실 수 있습니다.
Protalix BioTherapeutics (NYSE American: PLX) publiera ses résultats financiers pour le trimestre clos le 30 septembre 2025 et fournira une mise à jour commerciale le 13 novembre 2025.
La direction animera une conférence téléphonique à 8h00, heure normale de l’Est avec des numéros d’accès gratuits et internationaux et une diffusion en direct. Il est demandé aux participants de se connecter 15 minutes é2 avant pour s’inscrire et installer tout logiciel audio requis. Une rediffusion sera disponible pendant deux semaines sur le calendrier des événements des investisseurs de l’entreprise.
Protalix BioTherapeutics (NYSE American: PLX) wird seine Finanzergebnisse für das Quartal mit dem Stichtag 30. September 2025 veröffentlichen und am 13. November 2025 ein Geschäftsupdate geben.
Die Geschäftsführung wird eine Telefonkonferenz um 8:00 Uhr Eastern Standard Time mit kostenfreien und internationalen Einwahldaten sowie einem Live-Webcast abhalten. Die Teilnehmenden werden gebeten, 15 Minuten vor Beginn beizutreten, um sich zu registrieren und ggf. erforderliche Audio-Software zu installieren. Eine Wiederholung wird zwei Wochen lang im Kalender der Investorenveranstaltungen des Unternehmens verfügbar sein.
Protalix BioTherapeutics (NYSE American: PLX) ستطرح نتائجها المالية للربع المنتهي في 30 سبتمبر 2025 وتقدم تحديثاً تجارياً في 13 نوفمبر 2025.
١تقديم للماقدين المتَصفات تنويم القيم 8:00 صباحاً بتوقيت شرق الولايات المتحدة مع أرقام وصول مجانية وداخلية وبث مباشر عبر الإنترنت. تلزمينين المشاغرين المتر1يرين ال%D9%85دعیا 15 منظكة للاشتراك وتثبيت أية برامج صوتية مطلوبة. يقال البريات ستتوفر لمدة أسبوعين في تقويم فعاليات المستثمرين بالشركة.
- None.
- None.
Company to host conference call and webcast at 8:00 a.m. EST
CARMIEL,
Management will host a conference call to discuss the financial results and provide an update on recent developments.
Conference Call Details:
Date: Thursday, November 13, 2025
Time: 8:00 a.m. Eastern Standard Time (EST)
Toll Free: 1-877-423-9813
International: 1-201-689-8573
Israeli Toll Free: 1-809-406-247
Conference ID: 13757080
Call me™: http://bit.ly/4qJnnhY
The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
Webcast Details:
The conference will be webcast live from the Protalix website and will be available via the following links:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://bit.ly/4nJBRM1
Conference ID: 13757080
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-third-quarter-2025-financial-and-business-results-on-november-13-2025-302606982.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When will Protalix (PLX) report third quarter 2025 results?
What time is the Protalix (PLX) conference call on November 13, 2025?
How can investors join the Protalix (PLX) November 13, 2025 webcast?
What is the Protalix (PLX) conference call ID for November 13, 2025?
What phone numbers can I use to dial into the Protalix (PLX) earnings call?
Will the Protalix (PLX) November 13, 2025 call be available after the live event?
